{
    "clinical_study": {
        "@rank": "63643", 
        "arm_group": {
            "arm_group_label": "Prostate Cancer Imaging", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will receive multi-sequence Magnetic Resonance Imaging (MRI) of the prostate and pelvis. This scan will take approximately 90 minutes.\nIn addition, a 18F-Choline PET/CT(Positron emission tomography/computed tomography) scan of the abdomen and pelvis is performed. This scan will take about 30 minutes. Subjects may receive an additional 30 minute scan, if needed.\nPatients participating in an active surveillance program at the University of Michigan may receive yearly imaging followed by a prostate biopsy procedure."
        }, 
        "brief_summary": {
            "textblock": "This is an explorative diagnostic basic research study to assess the value of 18F-choline\n      PET/CT and multi-sequence MRI for prostate cancer in patients undergoing diagnostic prostate\n      biopsy. Patients will receive image-guided (targeted) prostate biopsies and metabolomic\n      profiling of prostate biopsy tissues to evaluate underlying metabolic changes in comparison\n      with pathological Gleason grading."
        }, 
        "brief_title": "Choline PET/CT and MRI for Targeted Prostate Biopsy", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males 40 years of age or older scheduled for prostate biopsy (for known or suspected\n             prostate cancer) followed by planned prostatectomy (population group A)\n\n          -  Males 40 years of age or older with known (biopsy\u2010confirmed) primary adenocarcinoma\n             of the prostate undergoing active surveillance scheduled for prostate biopsy\n             (population group B)\n\n        Exclusion Criteria:\n\n          -  Androgen ablation (hormone treatment) within the last 3 months\n\n          -  Prostate biopsy within 6 weeks prior to PET or MRI imaging\n\n          -  Active inflammatory bowel disease within the last 6 months\n\n          -  Acute prostatitis within the last 6 months\n\n          -  A non\u2010urologic bacterial infection requiring active treatment with antibiotics\n\n          -  Active other malignancy (except basal cell or squamous cell skin cancer) within the\n             last 2 years\n\n          -  Previous radiation treatment of the pelvis\n\n          -  Symptomatic distal rectal stenosis\n\n          -  Known hypersensitivity to glucagon\n\n          -  Pheochromocytoma, insulinoma or galactosemia\n\n          -  Insulin\u2010dependent diabetes"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01751737", 
            "org_study_id": "HUM00059514"
        }, 
        "intervention": {
            "arm_group_label": "Prostate Cancer Imaging", 
            "description": "After imaging is completed, subjects will be scheduled for a prostate biopsy  performed as part of their clinical care.  If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies.  These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.", 
            "intervention_name": "Prostate Cancer Imaging", 
            "intervention_type": "Procedure"
        }, 
        "intervention_browse": {
            "mesh_term": "Choline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "prostate", 
            "cancer", 
            "biopsy", 
            "18F-choline", 
            "PET", 
            "MRI"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "location": {
            "contact": {
                "email": "mpiert@umich.edu", 
                "last_name": "Morand R. Piert, M.D.", 
                "phone": "734-936-5388"
            }, 
            "contact_backup": {
                "email": "jemhill@umich.edu", 
                "last_name": "Jeanne Hill", 
                "phone": "734-647-9546"
            }, 
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109"
                }, 
                "name": "University of Michigan Health Systems"
            }, 
            "investigator": {
                "last_name": "Morand R. Piert, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Investigation of the Magnitude of Uptake, Retention, and Spatial Distribution Pattern of 18F-Choline in Comparison With MRI and Histology Obtained From Prostate Cancer Biopsies", 
        "overall_contact": {
            "email": "mpiert@umich.edu", 
            "last_name": "Morand R. Piert, M.D.", 
            "phone": "734-936-5388"
        }, 
        "overall_contact_backup": {
            "email": "jemhill@umich.edu", 
            "last_name": "Jeanne Hill", 
            "phone": "734-647-9546"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan Hospital", 
            "last_name": "Morand R. Piert, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Evaluation whether the odds of primary Gleason \u2265 3+4 are greater for image-guided biopsy (based on parametric PET/MRI) than for non-image-guided (standard) biopsy.", 
            "safety_issue": "Yes", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01751737"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan", 
            "investigator_full_name": "Morand Piert, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Michigan", 
        "sponsors": {
            "collaborator": {
                "agency": "Department of Defense", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "University of Michigan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}